TNF inhibitors for treatment of bowel disease not linked with increased risk of cancer

June 17, 2014

In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years, although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded, according to a study in the June 18 issue of JAMA.

Tumor necrosis factor α (TNF-α) antagonists are drugs that have been shown to be beneficial in reducing the inflammation in inflammatory diseases such as rheumatoid arthritis, and (IBD) (Crohn disease and ulcerative colitis). The therapeutic benefits of TNF-α antagonists must be weighed against the potential for adverse effects, including a possible increased risk of cancer. "Therefore, long-term observational studies of consequences of treatment with TNF-α antagonists are needed," the authors write.

Nynne Nyboe Andersen, M.D., of the Statens Serum Institut, Copenhagen, and colleagues studied cancer rates in patients with IBD exposed to TNF-α antagonists, as compared with patients with IBD not exposed to these drugs. The study included 56,146 patients (15 years or older) with IBD identified in the National Patient Registry of Denmark (1999-2012), of whom 4,553 (8.1 percent) were treated with TNF-α antagonists. Cancer cases were identified in the Danish Cancer Registry.

In total, 3,465 patients with IBD unexposed to TNF-α antagonists (6.7 percent) and 81 exposed to TNF-α antagonists (1.8 percent; median follow-up, 3.7 years) developed cancer. The study results indicated that exposure to TNF-α antagonists was not associated with an increased overall cancer risk. In addition, no site-specific cancers were observed in significant excess.

The authors note that because of the relatively small sample size and the small number of cancer cases in this study, statistical power was limited in analyses of site-specific and also for analyses stratified according to certain criteria, such as duration of follow-up.

"An increased risk of malignancy in the long term or with increasing number of cumulative doses of TNF-α antagonists cannot be excluded, and continuous follow-up of exposed is needed."

More information: DOI: 10.1001/jama.2014.5613

Related Stories

Adhesion molecule shows promise for treating colitis

April 29, 2014

The adhesion molecule CD146 plays a vital role in inflammation and offers a promising therapeutic target for treating inflammatory bowel disease (IBD) as well as preventing colitis-associated colorectal cancer, say scientists. ...

Low vitamin D levels tied to increased cancer risk in IBD

May 6, 2014

(HealthDay)—Low plasma levels of 25-hydroxyvitamin D (25[OH]D) are associated with an increased risk of cancer in patients with inflammatory bowel diseases (IBD), according to a study published in the May issue of Clinical ...

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

ALinC
not rated yet Jun 18, 2014
This just isn't a good article. The number of exposed patients vs not exposed patients is not even close to a balanced number, therefore making this study something close to worthless.
I'd tell anyone considering getting these drugs, to thoroughly research and know what these drugs do to the body before agreeing to the treatment. Most doctors have gotten very comfortable treating their patients with these chemicals. They prob. won't tell you much about the 3 pages of potential side-effects either. I've also noticed that doctors may not even take genetics into consideration to assess if the patient is a good candidate for this type of treatment. These drugs are not appropriate treatments for everyone. Know the facts about these drugs by researching things yourself.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.